Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer

Gynecologic and Obstetric Investigation

Volumn 47, Issue 3, 1999, Pages 200-204

  Saltzman, Andrew K ^a,b   Hartenbach, Ellen M ^a   Carter, Jonathan R ^a   Contreras, Diana N ^a   Twiggs, Leo B ^a   Carson, Linda F ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Ascites; ELISA; Ovarian cancer; Serum; Transforming growth factor

Indexed keywords

CYTOKINE; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; ASCITES; BLOOD LEVEL; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; HUMAN; LAPAROTOMY; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL; PROGNOSIS; SERUM;

EID: 0032968752     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010095     Document Type: Article

References (23)

1. Morrow CP, Curtin JP, Townsend DE: Synopsis of Gynecologic Oncology, ed 4. New York, Churchill Livingstone, 1993.
2. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
3. Baker VV: Molecular biology and genetics of epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994;21:25-40.
4. Kvale G, Heuch J, Nilssen S, Beral V: Reproductive factors and risk of ovarian cancer: A prospective study. Int J Cancer 1988;42:246-251.
5. Aaronson SA: Growth factors and cancer. Science 1991;254:1146-1153.
6. EIg SA, Yu Y, Carson LF, Adcock LL, Twiggs LB, Prem KA, Ramakrishnan S: Serum levels of macrophage colony-stimulating factor in patients with ovarian cancer undergoing second-look laparotomy. Am J Obstet Gynecol 1992; 166:134-137.
7. Moradi MM, Carson LF, Weinberg B, Haney AF. Twiggs LB, Ramakrishnan S: Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993;72: 2433-2440.
8. Stromberg K, Collins TJ, Gordon AW, Jackson CL, Johnson GR: Transforming growth factor-α acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res 1992;52:341-347.
9. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-712.
10. Hanauske AR, Arteaga CL, Clark GM, Buchok J, Marshall M, Hazarika P, Pardue RL, Von Hoff DD: Determination of transforming growth factor activity in effusions from cancer patients. Cancer 1988;61:1832-1837.
11. Arteaga CL, Hanauske AR, Clark GM, Osborne CK, Hazarika P, Pardue RL, Tio F, Von Hoff DD: Immunoreactive a transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res 1988;48:5023-5028.
12. Ridderheim M, Cajander S, Tavelin B, Stendahl U, Backstrom T: EGFATGF-α and progesterone in urine of ovarian cancer patients. Anticancer Res 1994;14:2119-2124.
13. Morishige K, Kurachi H, Amemiya K, Adachi H, Inoue M, Miyake A, Tanizawa O, Sakoyama Y: Involvement of transforming growth factor-α/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro. Cancer Res 1991;51:5951-5955.
14. Kurachi H, Morishige K, Amemiya K, Adachi H, Hirota K, Miyake A, Tanizawa O: Importance of transforming growth factor-α/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res 1991;51:5956-5959.
15. Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA-125) associated with human epithelial ovarian carcinomas. Cancer Res 1984;44: 1048-1053.
16. Owens OJ, Leake RE: Growth factor content in normal and benign ovarian tumours. Eur J Obstet Gynecol 1992;47:223-228.
17. Owens OJ, Stewart C, Leake RE: Growth factors in ovarian cancer. Br J Cancer 1991;64: 1177-1181.
18. Kommoss F, Wintzer HO, von Kleist S, Kohler M, Walker R, Langton B, Tran KV, Pfleiderer A, Bauknecht T: In situ distribution of transforming growth factor a in normal human tissues and in malignant tumours of ovary. J Pathol 1990;163:223-230.
19. Wilson AP, Fox H, Scott IV, Lee H, Dent M, Golding PR: A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours. Br J Cancer 1991;63:102-108.
20. Derynck R: Transforming growth factor-α: Structure and biological activities. J Cell Biochem 1986;32:293-304.
21. Slamon DJ, Godolphin W, Jones LA, Hol JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
22. Berchuck A, Kamel A, Whitaker R, Bast RC Jr: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
23. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-674.